2025-07-28T11:41:12-05:00 2024-12-31 872525370 CITRIN COOPERMAN ADVISORS LLC 50 ROCKEFELLER PLAZA NEW YORK NY 10020 990 2024-01-01 141935776 LUNG CANCER RESEARCH FOUNDATION LUNG 2125881580 PO BOX 780990 PHILADELPHIA PA 191780990 AUBREY RHODES EXECUTIVE DIRECTOR 2125881580 2025-07-25 1 0 AMANDA ADAMS P00748038 2126971000 2025-07-25 2024 2025-03-06 01:10:19Z X AUBREY RHODES PO BOX 780990 PHILADELPHIA PA 191780990 7843982 0 X WWW.LCRF.ORG X 2005 NY THE MISSION OF THE LUNG CANCER RESEARCH FOUNDATION IS TO IMPROVE LUNG CANCER OUTCOMES BY FUNDING RESEARCH FOR THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF LUNG CANCER. 16 16 24 98 0 0 6148851 7508888 0 0 212398 273635 25923 -377418 6387172 7405105 2481669 2607175 0 0 2473909 2523711 0 0 906180 1467868 1135711 6423446 6266597 -36274 1138508 6946397 7529664 3310501 2703563 3635896 4826101 X THE MISSION OF THE LUNG CANCER RESEARCH FOUNDATION IS TO IMPROVE LUNG CANCER OUTCOMES BY FUNDING RESEARCH FOR THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF LUNG CANCER. 0 0 2607175 2607175 RESEARCH: EACH YEAR, LCRF AWARDS RESEARCH GRANTS TO RECIPIENTS AROUND THE WORLD THAT DEMONSTRATE PROMISE AND INGENUITY IN THEIR WORK. INVESTIGATORS ARE SELECTED FROM HUNDREDS OF APPLICANTS AND REPRESENT SOME OF THE BRIGHTEST MINDS COMMITTED TO IMPROVING OUTCOMES FOR LUNG CANCER PATIENTS. THEY COME FROM VARIOUS CAREER PATHS INCLUDING SCIENTISTS, PHYSICIANS, STUDENTS, AND FELLOWS, AND WORKING ON A VARIETY OF INNOVATIVE RESEARCH PROJECTS RELATED TO LUNG CANCER RESEARCH.SEE SCHEDULE O FOR ADDITIONAL INFORMATION. 2440362 PATIENT EDUCATION & OUTREACH: WE PROVIDE UP-TO-DATE AND CREDIBLE SOURCES OF INFORMATION ON DIAGNOSIS, TREATMENT, AND WHAT TO EXPECT FROM TREATMENT THROUGH OUR FREE EDUCATIONAL MATERIALS. WE ALSO HAVE TOOLS TO HELP YOU FACILITATE DISCUSSIONS WITH YOUR HEALTHCARE TEAM SO YOU CAN PLAY AN ACTIVE ROLE IN TREATMENT DECISIONS. OUR MATERIALS ARE AVAILABLE IN BOTH DIGITAL DOWNLOAD AND PRINT FORMAT.SEE SCHEDULE O FOR ADDITIONAL INFORMATION. 5047537 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 28 0 1 24 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 16 16 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY AL AR FL GA KS KY ME MD MA MI MN HI NH NJ NC TN UT VA SC OR ND WA WV WI MS AK CA CO CT IL NM OH OK PA RI X X KELLY BULLOCK 2125881580 PO BOX 780990 PHILADELPHIA PA 191780990 COLLEEN CONNOR-ZIEGLER CHAIR 5.00 X X 0 0 0 BRENDON M STILES MD VICE CHAIR 3.00 X X 0 0 0 REINA HONTS VICE CHAIR 3.00 X X 0 0 0 AARON M TIGHE TREASURER 3.00 X X 0 0 0 BRUCE DUNBAR SECRETARY 1.00 X X 0 0 0 RAY E CHALME DIRECTOR 1.00 X 0 0 0 MATTHEW CIPRIANI DIRECTOR 1.00 X 0 0 0 PETER FRY DIRECTOR 1.00 X 0 0 0 JILL FURMAN DIRECTOR 1.00 X 0 0 0 JILL MORNINGSTAR DIRECTOR 1.00 X 0 0 0 SCOTT MORRIS DIRECTOR 1.00 X 0 0 0 KATE O'DONNELL DIRECTOR 1.00 X 0 0 0 KATERINA POLITI PHD DIRECTOR 1.00 X 0 0 0 TEJAL PATEL DIRECTOR 1.00 X 0 0 0 JOAN H SCHILLER MD DIRECTOR 1.00 X 0 0 0 MARY ANN TIGHE DIRECTOR 1.00 X 0 0 0 ROSE ANN WEINSTEIN DIRECTOR 1.00 X 0 0 0 KELLY A BULLOCK SR. DIRECTOR, FINANCE & ADMIN 40.00 X 126230 0 38186 AUBREY RHODES EXECUTIVE DIRECTOR 40.00 X 199958 0 24335 ANTOINETTE WOZNIAK CHIEF SCIENTIFIC OFFICER 40.00 X 224459 0 34565 STACEY BOWERS SR. DIRECTOR, PARTNERSHIPS 40.00 X 133569 0 43658 DHRUBA DEB SR. DIRECTOR, RESEARCH & ADMIN 40.00 X 122958 0 14592 NATALIE REILLY-FINCH SR. DIRECTOR, PHILANTHROPY 40.00 X 137596 0 4128 SHEILA SULLIVAN SR. DIRECTOR, MARKETING & COMMUNICATIONS 40.00 X 134779 0 36107 1079549 0 195571 7 0 1 0 YORK GRAPHIC SERVICES 3650 WEST MARKET STREET YORK PENNSYLVANIA PA 17404 DESIGN, PRODUCE, AND DISTRIBUTE LUNG CAN 183074 1 1858719 5650169 7508888 273635 273635 61459 1858719 438877 -377418 -377418 7405105 0 0 -103783 2607175 2607175 648036 337527 243221 67288 1402031 925287 4292 472452 44475 28906 1329 14240 267036 172454 10933 83649 162133 100522 17835 43776 55106 48720 6386 47390 35670 4046 7674 194379 178846 4181 11352 120023 108501 11522 170239 153007 940 16292 247799 195761 9912 42126 78560 62063 3142 13355 79706 62968 3188 13550 3664 2895 147 622 21676 17124 867 3685 BANK FEES 69805 2461 67344 BAD DEBTS 20109 20109 STATE FILING FEES 17144 17144 PROGRAM MATERIALS 10111 10111 6266597 5047537 312880 906180 X 20470 8188 0 12282 669589 1558716 5298125 5534215 732857 223370 600 140415 124646 55000 55000 0 0 104811 88717 6946397 7529664 419291 619504 2423603 1454059 401269 630000 66338 0 3310501 2703563 X 1662625 4165952 1973271 660149 3635896 4826101 6946397 7529664 X 1138508 51697 X 0 1 X 1 0 X 5465693 6344359 7013446 6148851 7508888 32481237 5465693 6344359 7013446 6148851 7508888 32481237 5991724 26489513 1357 1402 28829 212398 273635 517621 25923 25923 33024781 7723 0.80210 0.81290 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 55000 55000 0 0 X 9954789 2549684 2549684 7405105 0 7405105 8764584 2549684 2549684 6214900 51697 51697 6266597 PART X, LINE 2: THE FOUNDATION RECOGNIZES AND MEASURES ITS UNRECOGNIZED TAX BENEFITS IN ACCORDANCE WITH FASB ASC 740, INCOME TAXES. UNDER THAT GUIDANCE, THE FOUNDATION ASSESSES THE LIKELIHOOD, BASED ON THEIR TECHNICAL MERIT, THAT TAX POSITIONS WILL BE SUSTAINED UPON EXAMINATION BASED ON THE FACTS, CIRCUMSTANCES AND INFORMATION AVAILABLE AT THE END OF EACH PERIOD. THE MEASUREMENT OF UNRECOGNIZED TAX BENEFITS IS ADJUSTED WHEN NEW INFORMATION IS AVAILABLE, OR WHEN AN EVENT OCCURS THAT REQUIRES A CHANGE. MANAGEMENT HAS EVALUATED THE FOUNDATION'S TAX POSITIONS AND BELIEVES THAT THE FOUNDATION HAS TAKEN NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE ADJUSTMENTS TO THE FINANCIAL STATEMENTS. PART XII, LINE 4B - OTHER ADJUSTMENTS: RETURNED GRANT FUNDS NETTED AGAINST EXPENSE 51,697. GALA 660962 599503 61459 104198 62679 ELLIOT'S LEGACY 380355 380355 6630 120054 10 878861 878861 3059 142257 1920178 1858719 61459 113887 324990 438877 -377418 1 ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX NY 104611975 830621846 501(C)(3) 150000 0 RESEARCH AMERICAN SOCIETY OF THE ITALIAN LEGIONS OF MERIT EIGHT EAST 69TH STREET NEW YORK NY 10021 136201420 501(C)(3) 320000 0 RESEARCH ALUMNI ASSOCIATION OF THE UNIVERSITY OF MICHIGAN 200 FLETCHER STREET ANN ARBOR MI 481091007 237206591 501(C)(3) 231130 0 RESEARCH BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 77030 741613878 501(C)(3) 29890 0 RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER INC 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 10675 0 RESEARCH BOSTON MEDICAL CENTER CORPORATION ONE BOSTON MEDICAL CENTER PLACE BOSTON MA 02118 043314093 501(C)(3) 6405 0 RESEARCH DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 042263040 501(C)(3) 800620 0 RESEARCH DARTMOUTH-HITCHCOCK CLINICAL TRIALS ONE MEDICAL CENTER DRIVE LEBANON NH 03756 222519596 501(C)(3) 8540 0 RESEARCH HARTFORD HEALTHCARE CORPORATION 100 PEARL STREET HARTFORD CT 06103 222672834 501(C)(3) 10675 0 RESEARCH H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC PO BOX 406249 ATLANTA GA 30384 593238634 501(C)(3) 14945 0 RESEARCH MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 25620 0 RESEARCH MEDICAL UNIVERSITY OF SOUTH CAROLINA 1 SOUTH PARK CIRCLE BUILDING 1 STREET 402 CHARLESTON CHARLESTON SC 29407 576000722 501(C)(3) 21350 0 RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 176000 0 RESEARCH OHIO STATE UNIVERSITY FOUNDATION 14 E 15TH AVENUE 4TH FL COLUMBUS OH 43201 311145986 501(C)(3) 29890 0 RESEARCH OREGON HEALTH & SCIENCE UNIVERSITY FOUNDATION 2020 SW 4TH AVENUE SUITE 900 PORTLAND OR 97201 237083114 501(C)(3) 150000 0 RESEARCH PROVIDENCE HEALTH & SERVICES - OREGON 1801 LIND AVENUE SW ATTN TAX DEPARTMENT RENTON WA 98057 510216587 501(C)(3) 21350 0 RESEARCH THE BRIGHAM & WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON MA 02115 042312909 501(C)(3) 36295 0 RESEARCH THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131 STREET MC 8741 NEW YORK NY 100277922 135598093 501(C)(3) 162810 0 RESEARCH THE UC DAVIS FOUNDATION 202 COUSTEAU PLACE SUITE STREET 185 DAVIS CA 95618 946081352 501(C)(3) 17080 0 RESEARCH UCLA 10889 WILSHIRE BOULEVARD SUITE 1100 LOS ANGELES CA 90024 952250801 501(C)(3) 199105 0 RESEARCH UNIVERSITY Y OF THE UNIVERSITY OF MISSOURI - COLUMBIA AMY SMITH COLUMBIA MO 652117100 431143471 501(C)(3) 21350 0 RESEARCH YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS PO BOX 1873 NEW HAVEN CT 06508 060646973 501(C)(3) 150000 0 RESEARCH WASHINGTON UNIVERSITY IN ST LOUIS PO BOX 505505 ST LOUIS MT 63150 430653611 501(C)(3) 8540 0 RESEARCH 23 0 PART I, LINE 2: GRANT PROCESS IS PUBLIC, LOIS AND PROPOSALS ARE REVIEWED, SCORED, AND SELECTED BY THE SCIENTIFIC ADVISORY BOARD AND SCIENTIFIC EXECUTIVE COMMITTEE. EACH AWARDEE MUST SUBMIT A SIGNED AGREEMENT, BUDGET, ANNUAL STATUS UPDATE REPORTS, AND A FINAL BUDGET AT TERM. X X 0 0 0 0 0 0 0 0 0 ANTOINETTE WOZNIAK CHIEF SCIENTIFIC OFFICER 224459 0 0 0 0 0 0 0 34565 0 259024 0 0 0 AUBREY RHODES EXECUTIVE DIRECTOR 199958 0 0 0 0 0 8154 0 16181 0 224293 0 0 0 STACEY BOWERS SR. DIRECTOR, PARTNERSHIPS 133569 0 0 0 0 0 5504 0 38154 0 177227 0 0 0 SHEILA SULLIVAN SR. DIRECTOR, MARKETING & COMMUNICAT 134779 0 0 0 0 0 5514 0 30593 0 170886 0 0 0 KELLY A BULLOCK SR. DIRECTOR, FINANCE & ADMIN 126230 0 0 0 0 0 5277 0 32909 0 164416 0 0 0 FORM 990, PART III LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS: RESEARCH: DESPITE BEING THE LEADING CAUSE OF CANCER MORTALITY, LUNG CANCER RECEIVES FAR LESS RESEARCH FUNDING PER DEATH. LUNG CANCER RECEIVES $4,440 PER DEATH COMPARED TO BREAST CANCER AT $20,238, PROSTATE CANCER AT $9,200, AND PANCREATIC CANCER AT $6,020. THAT IS WHY FUNDING FROM NON-GOVERNMENTAL ORGANIZATIONS IS SO CRITICAL. THE LUNG CANCER RESEARCH FOUNDATION (LCRF) PLAYS A PIVOTAL ROLE IN THIS FUNDING LANDSCAPE. SINCE 2005, THE LUNG CANCER RESEARCH FOUNDATION, AND ITS PROGENITOR ORGANIZATIONS, HAS BEEN COMMITTED TO FUNDING CUTTING EDGE RESEARCH THAT TRANSFORMS THE LUNG CANCER TREATMENT LANDSCAPE. WHEN WE FIRST OPENED OUR DOORS, OUR MISSION WAS SIMPLE: PROVIDE HOPE BY FUNDING THE BEST RESEARCH AND HELP BRING IT TO PEOPLE. WE HAVE BEEN WILDLY SUCCESSFUL. IN 18 YEARS, WE HAVE BECOME ONE OF THE LARGEST PRIVATE FUNDERS OF LUNG CANCER RESEARCH ENABLING EARLIER DETECTION, DEEPER UNDERSTANDING OF THE MECHANISMS THAT ALLOW LUNG CANCER TO FORM, AND NEW AND EXPANDED TREATMENT OPTIONS THAT HAVE SAVED MANY LIVES. SIMULTANEOUSLY, OUR SCIENTIFIC ADVISORY BOARD HAS BECOME ONE OF THE PREEMINENT BODIES IN THE LUNG CANCER RESEARCH COMMUNITY. FURTHERMORE, OUR INVESTMENT IN EARLY CAREER INVESTIGATORS CONTINUES TO ALLOW NEW TALENT TO THRIVE AND GROW IN THE SPACE AS IS DEMONSTRATED THROUGH FOLLOW-ON FUNDING MANY HAVE RECEIVED SINCE RECEIVING THEIR LCRF GRANT. TO DATE, LCRF HAS PROVIDED 429 RESEARCH GRANTS TOTALING NEARLY $48 MILLION, THE LARGEST AMOUNT PROVIDED BY A NON-GOVERNMENTAL ORGANIZATION DEDICATED TO FUNDING LUNG CANCER RESEARCH. SUPPORT WITHIN THE PATIENT COMMUNITY, RESEARCHERS, STRATEGIC PARTNERS, AND INDUSTRY PARTNERS IS KEY TO OUR PRESENT SUCCESS AS WELL AS ACHIEVING OUR FUTURE VISION TO FIND A CURE FOR LUNG CANCER. THE 2024 GRANT CYCLE INCLUDED AWARDS IN THE FOLLOWING AREAS: LCRF LEADING-EDGE GRANT IN LUNG CANCER, LCRF RESEARCH GRANT ON EARLY DETECTION AND PRE-NEOPLASIA IN LUNG CANCER, LCRF RESEARCH GRANTS ON UNDERSTANDING RESISTANCE IN LUNG CANCER, LCRF MINORITY CAREER DEVELOPMENT AWARD (CDA) FOR LUNG CANCER, AND THE IASLC-LCRF TEAM SCIENCE RESEARCH GRANT ON THE NEXT STEP IN THE CURE OF ONCOGENE-DRIVEN LUNG CANCERS. EARLIER THIS YEAR, LCRF AWARDED THE AMERICAN LUNG CANCER SCREENING INITIATIVE (ALCSI), LED BY CHI-FU JEFFREY YANG, MD, OF MASSACHUSETTS GENERAL HOSPITAL, A $320,000 GRANT TO CONDUCT ITS "PLUS ONE" SCREENING INITIATIVE AND RESEARCH STUDY. TWO (2) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF LEADING EDGE RESEARCH GRANT PROGRAM WHICH FUNDS INNOVATIVE PROJECTS ACROSS THE FULL SPECTRUM OF BASIC, TRANSLATIONAL, CLINICAL, EPIDEMIOLOGICAL, HEALTH SERVICES, AND RESEARCH FOCUSED ON A MYRIAD OF TOPICS. TWO (2) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF RESEARCH GRANT ON UNDERSTANDING RESISTANCE IN LUNG CANCER. THESE PROJECTS WILL FOCUS ON UNDERSTANDING THE DEVELOPMENT, PREVENTION, AND THERAPY OF RESISTANCE BY SUPPORTING PROJECTS THAT ARE IDENTIFYING, CHARACTERIZING, TREATING OR PREVENTING RESISTANCE TO THERAPIES IN LUNG TUMOR CELLS, TISSUES, MOUSE MODELS, AND/OR PATIENTS. THESE STUDIES WILL ENHANCE THE MOMENTUM OF IMPROVING LUNG CANCER OUTCOMES AND HAVE THE POTENTIAL TO INCREASE SURVIVORSHIP. TWO (2) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF MINORITY CAREER DEVELOPMENT AWARD (CDA). MINORITY APPLICANTS ARE LESS LIKELY TO RECEIVE GRANTS, TO HAVE THE R PHASES OF K01 OR K99 AWARDS ACTIVATED, NEED MORE SUBMISSIONS TO OBTAIN FUNDING, AND OFTEN WILL NOT RESUBMIT PROPOSALS. AS MINORITY APPLICANTS MUST OVERCOME SYSTEMIC AND STRUCTURAL BARRIERS DUE TO RACE, ETHNICITY, COUNTRY OF ORIGIN, SOCIOECONOMIC STATUS, AND/OR LANGUAGE, MANY LEAVE ACADEMIA WHICH FURTHER EXACERBATES THE LACK OF DIVERSITY IN SCIENCE, TECHNOLOGY, ENGINEERING AND MATHEMATICS (STEM) AND MEDICAL FIELDS. TO PROVIDE PROTECTED TIME AND MENTORING TO THESE TRAINEES, WE CONTINUE TO OFFER THE LCRF MINORITY CAREER DEVELOPMENT AWARD (CDA) FOR LUNG CANCER FOR MINORITY POSTDOCTORAL/CLINICAL FELLOWS AND ASSISTANT PROFESSORS WITHIN 10 YEARS OF COMPLETING THEIR MD AND/OR PHD DEGREES TO SUBMIT PROPOSALS. ONE (1) RESEARCH GRANT WAS FUNDED THROUGH THE LCRF RESEARCH GRANT ON EARLY DETECTION AND PRE-NEOPLASIA IN LUNG CANCER. GIVEN THE SIGNIFICANCE AND NEED FOR EARLY DETECTION OF LUNG CANCER AND ADVANCEMENTS IN MOLECULAR SCREENING, LCRF CONTINUES TO OFFER A FUNDING MECHANISM TO SUPPORT RESEARCH PROJECTS THAT FACILITATE OR ADVANCE THE UNDERSTANDING AND CHARACTERIZATION OF PRE-NEOPLASIA OR APPROACHES FOR EARLY DETECTION OF LUNG CANCER. WORK SUPPORTED THROUGH THIS MECHANISM ADDRESSES IMPORTANT QUESTIONS IN NON-SMALL CELL AND SMALL CELL LUNG CANCER. IN PARTNERSHIP WITH THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC), THE IASLC-LCRF TEAM SCIENCE RESEARCH GRANT ON THE NEXT STEP IN THE CURE OF ONCOGENE-DRIVEN LUNG CANCERS AWARD, IS A $2.5 MILLION AWARD OVER FOUR YEARS GRANTED TO A TEAM OF SCIENTISTS WHOSE COORDINATED PROJECTS ADVANCE RESEARCH IN ONCOGENE-DRIVEN LUNG CANCER WITH THE INTENT TO CULMINATE IN A CLINICAL TRIAL. IN ADDITION, THE FOUNDATION IS CURRENTLY ADMINISTRATING RESEARCH PARTNERSHIPS WITH THE LUNG CANCER MUTATION CONSORTIUM. LCRF'S PARTNERSHIP WITH THE LUNG CANCER MUTATION CONSORTIUM (LCMC) DATES BACK TO 2011 COVERING THREE CLINICAL TRIALS. THE LCMC2 CLINICAL TRIAL ENROLLED 1,000 PATIENTS VIA A NETWORK OF FOURTEEN (14) NOTABLE DOMESTIC CLINICAL RESEARCH SITES. THE CLINICAL TRIAL STUDIED THE IMPACT OF SMOKING AND TP53 MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WITH TARGETABLE MUTATIONS. THE LCMC3 CLINICAL TRIAL BEGAN IN 2017 AND HAS ENROLLED 1,000 PATIENTS VIA A NETWORK OF FIVE (5) DOMESTIC CLINICAL RESEARCH SITES. LCMC3 IS DESIGNED AS A NEOADJUVANT AND ADJUVANT TRIAL OF IMMUNE CHECKPOINT BLOCKADE FOR STAGE IB-IIIA NON-SMALL CELL LUNG CANCER. FINAL REPORTING FROM THIS CLINICAL TRIAL SHOULD BE COMPLETED IN LATE 2024. LAUNCHED IN LATE 2020, LCMC4 IS A STUDY WITH A GOAL OF ENLISTING 1,000 PATIENTS VIA A NETWORK OF 25+ DOMESTIC CLINICAL RESEARCH SITES. THE AIM OF THE CLINICAL TRIAL IS TO DETERMINE THE FEASIBILITY OF COMPREHENSIVE MOLECULAR PROFILING TO DETECT ACTIONABLE ONCOGENIC DRIVERS IN PATIENTS WITH SUSPECTED EARLY-STAGE LUNG CANCERS SCHEDULED TO UNDERGO BIOPSIES TO ESTABLISH THE DIAGNOSIS OF LUNG CANCER. SEVEN (7) GRANTS IN SUPPORT OF THE LCMC4 - LEADER NEOADJUVANT SCREENING TRIAL HAVE BEEN MADE. IN 2024, OUR RESEARCH INVESTMENT WAS FUNDED WITHOUT THE NEED FOR DEFICIT SPENDING, AND WE ARE POISED TO GROW OUR RESEARCH INVESTMENT IN THE COMING YEARS. FORM 990, PART III LINE 4B, PROGRAM SERVICE ACCOMPLISHMENTS: PATIENT EDUCATION & OUTREACH: THE PATIENT EDUCATION PORTFOLIO INCLUDES PRINT AND DIGITAL EDUCATIONAL RESOURCES (PDF DOWNLOADABLE FORMAT AS WELL AS EASILY ACCESSIBLE WEBSITE CONTENT) THAT ARE PROVIDED AT NO COST. THE OVERALL GOALS OF OUR PATIENT EDUCATION MATERIALS ARE TO HELP PATIENTS AND THEIR FAMILIES BETTER UNDERSTAND LUNG CANCER, LEARN ABOUT TREATMENT OPTIONS, PARTICIPATE IN SHARED DECISION MAKING WITH THEIR CARE TEAM, MAKE DECISIONS ABOUT CLINICAL TRIALS, AND UNDERSTAND THE IMPLICATIONS OF COMPREHENSIVE BIOMARKER TESTING. PATIENTS AND CAREGIVERS NEED INFORMATION AT ALL STEPS IN THE CONTINUUM OF CARE, FROM DIAGNOSIS THROUGH TREATMENT AND BEYOND. THE LUNG CANCER RESEARCH FOUNDATION HAS A PORTFOLIO OF EDUCATIONAL RESOURCES TO HELP PATIENTS AND THEIR FAMILIES BETTER UNDERSTAND LUNG CANCER AND LEARN ABOUT THEIR TREATMENT OPTIONS. HELPING PATIENTS TO UNDERSTAND NEW TREATMENTS AND THE HOPE OFFERED BY THESE TREATMENT ADVANCES ARE KEY OBJECTIVES OF OUR EDUCATIONAL MATERIALS. WE ALSO HAVE MATERIALS DESIGNED TO EDUCATE THE PUBLIC ABOUT THE MAGNITUDE OF LUNG CANCER AS A HEALTH CARE PROBLEM AND WAYS TO IDENTIFY SYMPTOMS OF THE DISEASE. IN 2024, LCRF DISTRIBUTED OVER 368,000 EDUCATIONAL PIECES TO LUNG CANCER PATIENTS, CAREGIVERS, ADVOCATES AND HEALTHCARE PROFESSIONALS ACROSS THE NATION IN BOTH PRINT AND DIGITAL FORMAT. OUR WEBSITE ALSO CONTAINS LINKS TO INFORMATION AND RESOURCES, WHICH RECEIVES ON AVERAGE OF MORE THAN 380,000 PAGEVIEWS ANNUALLY. OUR CONTINUED GOAL IS TO STEADILY INCREASE OUR MATERIALS DISTRIBUTED, PARTICULARLY WITH DIGITAL DOWNLOADS AS THERE HAS BEEN A SURGE IN DEMAND FOR READILY AVAILABLE INFORMATION. THE KEY OBJECTIVES OF THE PORTFOLIO ARE TO: EMPOWER PATIENTS AND CAREGIVERS BY INCREASING THEIR KNOWLEDGE OF LUNG CANCER, BIOMARKER TESTING, CLINICAL TRIALS AND TREATMENT OPTIONS; PROVIDE AN UP-TO-DATE AND CREDIBLE SOURCE OF INFORMATION ON AVAILABLE TREATMENTS, EDUCATE PATIENTS ON WHAT TO EXPECT FROM TREATMENT AND WHAT IS CRITICAL FOR OPTIMAL OUTCOMES; PROVIDE TOOLS TO FACILITATE DISCUSSIONS BETWEEN PATIENTS AND HEALTHCARE PROVIDERS; EDUCATE THE PUBLIC ABOUT THE MAGNITUDE OF LUNG CANCER AS A HEALTH CARE ISSUE, WAYS TO IDENTIFY SYMPTOMS OF THE DISEASE, AND EXPLAIN THE IMPORTANCE OF EARLY DETECTION, TUMOR BIOMARKER TESTING AND CLINICAL TRIAL PARTICIPATION; SHARE PROGRESS AND IMPACT OF RESEARCH (INCLUDING THAT WHICH IS FUNDED BY LCRF), AND EXPLAIN WHY FUNDING RESEARCH IS CRUCIAL FOR THE DEVELOPMENT OF NEW TREATMENTS FOR LUNG CANCER; AND ENSURE THAT THE MATERIALS ARE CULTURALLY APPROPRIATE, AT APPROPRIATE LITERACY LEVELS, AND ACCESSIBLE THROUGH A VARIETY OF DELIVERY METHODS (ONLINE, THROUGH COMMUNITY GROUPS AND COMMUNITY HEALTHCARE PROVIDERS, PATIENT AND CAREGIVER FOCUSED EVENTS, ETC.). THE PATIENT EDUCATION MATERIALS ARE EVIDENCE-BASED AND DEVELOPED IN CONJUNCTION WITH THE EDUCATION AND ENGAGEMENT COMMITTEE, COMPOSED OF ONCOLOGISTS, RESEARCHERS, ONCOLOGY NURSES, SOCIAL WORKERS, AND PATIENTS/CAREGIVERS. THE PATIENT EDUCATIONAL PORTFOLIO IS ALSO CRAFTED WITH ASSISTANCE FROM THE FEEDBACK WE RECEIVE FROM OUR COMMUNITY. OUR MATERIALS ARE RATED ON AVERAGE A 4.6/5 ACCORDING TO THE FEEDBACK COLLECTED FROM INDIVIDUALS WHO DOWNLOAD OR ORDER OUR PRINT MATERIALS ON OUR WEBSITE. SAMPLE FEEDBACK INCLUDES: THANK YOU FOR PROVIDING FREE EDUCATIONAL RESOURCES. I AM A THORACIC NURSE NAVIGATOR AND PROVIDE THESE TO ALL OF MY LUNG CANCER PATIENTS. MY PATIENTS LIKE AND APPRECIATE THEM VERY MUCH. THANK YOU SO MUCH FOR PROVIDING INFORMATION TO PEOPLE TRYING TO NAVIGATE A LUNG CANCER DIAGNOSIS AND ALL THE STRESS RELATED TO THE ENTIRE PROCESS. MY MOTHER WAS RECENTLY DIAGNOSED WITH LUNG CANCER. VERY HEARTBREAKING AND A SURPRISE TO US ALL. HEARD NOTHING BUT GOOD REVIEWS ABOUT LCRF SO I LOOK FORWARD TO LEARNING ABOUT EVERYTHING AND I APPRECIATE WHAT YOU ALL DO. I LOVE THE LIVING WITH LUNG CANCER BOOKLET. IT IS DEFINITELY VERY COMPREHENSIVE IN THAT IT INCLUDES COPING WITH DIAGNOSIS/TREATMENT, INFORMATION ABOUT OUR NEWER TARGETED AND IMMUNOTHERAPIES, AND TREATMENT SIDE-EFFECT MANAGEMENT. GOOD JOB! LUNG CANCER SUPPORT LINE: OUR LUNG CANCER SUPPORT LINE IS A TOLL-FREE NUMBER (844)-835-4325, AND IS AVAILABLE TO ANYONE AFFECTED BY LUNG CANCER, PRIMARILY LUNG CANCER PATIENTS AND CAREGIVERS. THE SUPPORT LINE OPERATES MONDAY-FRIDAY 9AM-5PM ET, IS MANAGED BY A CLINICAL SOCIAL WORKER ON LCRF'S STAFF, AND IS EQUIPPED WITH EXTENSIVE AND UP-TO-DATE RESOURCE GUIDES FOR COMMON NEEDS AND SERVICES FOR LUNG CANCER PATIENTS SUCH AS FINANCIAL ASSISTANCE, TRANSPORTATION OR LODGING TO/FROM MEDICAL APPOINTMENTS, SUPPORT GROUPS, AND MUCH MORE. LUNG CANCER PATIENTS AND THEIR CAREGIVERS MAY CALL OR EMAIL THE PROGRAM AS OFTEN AS THEY WISH, AND THE SERVICE IS OFFERED FREE OF CHARGE. THE LUNG CANCER SUPPORT LINE HELPS FILL AN UNMET NEED BY PROVIDING PERSONALIZED, ONE-ON-ONE SUPPORT TO CALLERS WHO ARE FACING THE CHALLENGES OF LUNG CANCER. IN 2024, WE HAD OVER 1,700INQUIRIES COME IN THROUGH THE SUPPORT LINE. OVER HALF OF CALLERS ARE NEWLY DIAGNOSED PATIENTS OR CAREGIVERS OF THOSE WHO ARE RECENTLY DIAGNOSED, PROVING THAT THE SUPPORT LINE PROVIDES A TIMELY SERVICE FOR THOSE SEEKING SUPPORT. MANY SUPPORT LINE INQUIRIES ALSO COME IN FROM HEALTHCARE INSTITUTIONS OR COMMUNITY-BASED INSTITUTIONS LOOKING FOR RESOURCES FOR THEIR PATIENTS. OUR CONTINUED GOAL FOR THE SUPPORT LINE IS TO STRENGTHEN OUR COMMUNICATION WITH THOSE WHO ARE NEWLY DIAGNOSED AND ENGAGED IN OUR EDUCATIONAL PROGRAMS. WE ALSO HOPE TO INCREASE OUR SUPPORT LINE REACH BY 10% OVER THE NEXT YEAR VIA TARGETED OUTREACH AND PROMOTION OF OUR SERVICES. THROUGH THE SUPPORT LINE, WE: PROVIDE QUALITY SERVICE TO PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS, BY OFFERING SUPPORT IN THEIR AREA OF NEED DURING ONE-ON-ONE INTERACTIONS; EMPOWER PATIENTS AND CAREGIVERS THROUGH CONNECTIONS TO RESOURCES (EDUCATION, ASSISTANCE, AND SUPPORT); ENHANCE PATIENTS AND CAREGIVERS' UNDERSTANDING OF LUNG CANCER; INCREASE NUMBER OF SUPPORT INQUIRIES AND TOTAL NUMBER OF INTERACTIONS BETWEEN LCRF SUPPORT SERVICES STAFF AND PEOPLE SEEKING SUPPORT; AND INCREASE SUPPORT TO UNDERSERVED POPULATIONS BY DEVELOPING RELEVANT RESOURCE GUIDES THAT ADDRESS THE NEEDS OF SPECIFIC UNDERSERVED POPULATIONS (I.E.: PEOPLE OF COLOR, UNINSURED, LGBTQ+, NON-ENGLISH SPEAKING, CAREGIVERS, YOUNG ADULTS). PATIENT EDUCATION PROGRAMMING (VIRTUAL AND IN-PERSON): BARRIERS TO ACCESSING UP-TO-DATE, EXPERT INFORMATION ON LUNG CANCER RESEARCH ADVANCEMENTS AND TREATMENTS ARE EVIDENT BASED ON STIGMA SURROUNDING LUNG CANCER. OUR PATIENT EDUCATION PROGRAMMING AIMS TO INCREASE THE ACCESSIBILITY OF DISEASE AWARENESS AND INFORMATION TO THE LUNG CANCER COMMUNITY BY CREATING EVENTS WHERE LUNG CANCER RESEARCHERS, CLINICIANS, AND OTHER EXPERTS DISCUSS SCIENTIFIC ADVANCEMENT, IMPORTANT UPDATES IN TREATMENTS, AS WELL AS INFORMATION FOR IMPROVING QUALITY OF LIFE WHILE RECEIVING TREATMENT. LCRF ALSO AIMS TO HOST TOPICS THAT WOULD SPECIFICALLY HELP SUPPORT UNDERSERVED POPULATIONS, SUCH AS PEOPLE OF COLOR, THOSE IN LOW SOCIOECONOMIC GROUPS, RURAL DEMOGRAPHICS, AND SPANISH-SPEAKING POPULATIONS, ALL OF WHICH EXPERIENCE A RANGE OF HEALTH DISPARITIES. ATTENDEES, BOTH VIRTUAL AND IN-PERSON, HAVE THE OPPORTUNITY TO LEARN ABOUT LUNG CANCER, TREATMENT OPTIONS AND ADVANCES IN RESEARCH, CLINICAL TRIALS AND AVAILABLE RESOURCES. THEY CAN POSE QUESTIONS TO LUNG CANCER EXPERTS, SHARE THEIR OWN PERSONAL EXPERIENCE, AND ENGAGE WITH THEIR PEERS, FORGING CONNECTIONS AND SUPPORT. THIS PROGRAM ALLOWS PATIENTS AND THEIR FAMILIES TO BECOME MORE INFORMED ABOUT LUNG CANCER AND THEIR OPTIONS FOR NAVIGATING LIFE WITH THEIR DISEASE. FORM 990, PART III LINE 4B, PROGRAM SERVICE ACCOMPLISHMENTS, CONTINUED: THE LEARNING OBJECTIVES OF OUR EDUCATIONAL PROGRAMS ARE: 1. PROVIDE UP-TO-DATE EDUCATION AND INFORMATION ABOUT LUNG CANCER DIAGNOSIS AND TREATMENT, SO OUR AUDIENCE HAS A RELIABLE SOURCE TO TURN TO FOR ACCURATE AND TIMELY INFORMATION; 2. INFORM ABOUT NEW ADVANCEMENTS IN THE FIELD OF LUNG CANCER RESEARCH AND THE TREATMENT LANDSCAPE; 3. PROVIDE OPPORTUNITY FOR DIALOGUE AND A SENSE OF CONNECTION AND COMMUNITY; 4. HIGHLIGHT RESEARCH ADVANCEMENTS, NEWLY DISCOVERED TREATMENT OPTIONS, BEST PRACTICES AND STANDARDS OF CARE FOR PATIENTS UNDERGOING TREATMENT, AND PSYCHOSOCIAL SUPPORT FOR PATIENTS AND THEIR CAREGIVERS; 5. ENSURE AWARENESS OF AND ACCESS TO IMPORTANT LUNG CANCER RESOURCES AND PROGRAMS OFFERED THROUGH LCRF AND ITS PARTNERS. SINCE ITS INCEPTION IN MARCH 2020, WE'VE HAD OVER 10,000 REGISTRANTS FOR OUR #TOGETHERSEPARATELY VIRTUAL EVENTS WITH AN AVERAGE ATTENDANCE RECORD OF OVER 100 INDIVIDUALS PER WEBINAR. MOST OF THE ATTENDEES IN THIS SERIES ARE LUNG CANCER PATIENTS, SURVIVORS, ADVOCATES, CAREGIVERS, AND COMMUNITY PROVIDERS. OUR GOAL IS TO CONTINUE THE SERIES, WHILE FOCUSING ON THE BIGGEST AREAS OF UNMET NEEDS IN THE LUNG CANCER COMMUNITY. ADDITIONALLY, SINCE 2022, WE'VE REINTRODUCED OUR IN-PERSON PROGRAMMING WITH THE LAUNCH OF OUR LCRF TOGETHER IN-PERSON EDUCATIONAL PROGRAM SERIES. WE HOSTED ONE LCRF TOGETHER PROGRAM IN CHICAGO ON MAY 15, 2024. THIS EVENT HAD OVER 50 PEOPLE IN ATTENDANCE, INCLUDING PATIENTS AND CAREGIVERS, THOSE WHO HAVE LOST A LOVED ONE, AS WELL AS HEALTHCARE PROFESSIONALS AND INDUSTRY SPONSORS. ANOTHER LCRF TOGETHER PROGRAM WAS HELD IN TARRYTOWN, NEW YORK ON APRIL 13, 2024. FORM 990, PART VI, SECTION A, LINE 2 MARY ANN TIGHE AND AARON M. TIGHE - FAMILY RELATIONSHIP MARY ANN TIGHE AND RAYMOND E. CHALME - BUSINESS RELATIONSHIP FORM 990, PART VI, SECTION B, LINE 11B BOARD TREASURER, CEO, AND CFO REVIEW 990 PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD REVIEWS THE CONFLICT OF INTEREST POLICY ANNUALLY, AND ASKS ALL BOARD MEMBERS AND EMPLOYEES TO DISCLOSE ANY CONFLICTS OR POTENTIAL CONFLICTS. IN ADDITION, ALL CONTRACTS ARE REVIEWED FOR KNOWN OR POTENTIAL CONFLICTS BY THE BOARD OF DIRECTORS, EXECUTIVE DIRECTOR, SR. DIRECTOR FINANCE & ADMINISTRATION AND THE EXECUTIVE COMMITTEE ON AN ON-GOING BASIS. FORM 990, PART VI, SECTION B, LINE 15 THE EXECUTIVE COMMITTEE OF THE BOARD LOOKS AT COMPENSATION SURVEYS AND ALSO COMPARES SALARIES IN SIMILAR ORGANIZATIONS TO DETERMINE THE REASONABLENESS OF SALARIES FOR THE EXECUTIVE DIRECTOR. THE EXECUTIVE COMMITTEE ALSO CONSIDERS OTHER PERFORMANCE-BASED CRITERIA WHICH INCLUDES A WRITTEN PERFORMANCE APPRAISAL OF THE EXECUTIVE DIRECTOR. THE EXECUTIVE DIRECTOR APPROVES ALL OTHER SALARIES AND HAS OVERSIGHT IN ALL ANNUAL REVIEWS. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE. ALL OTHER DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON RECEIPT OF A WRITTEN REQUEST. FORM 990, PART XI, LINE 9: RETURNED GRANT FUNDS 51,697.